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Delayed healing and nonunion of fractures represent enormous burdens to patients and 
healthcare systems. There are currently no approved pharmacological agents for the treatment of 
established nonunions, or for the acceleration of fracture healing, and no pharmacological agents 
are approved for promoting the healing of closed fractures. Yet several pharmacologic agents 
have the potential to enhance some aspects of fracture healing. In preclinical studies, various 
agents working across a broad spectrum of molecular pathways can produce larger, denser and 
stronger fracture calluses. However, untreated control animals in most of these studies also 
demonstrate robust structural and biomechanical healing, leaving unclear how these 
interventions might alter the healing of recalcitrant fractures in humans. This review describes 
the physiology of fracture healing, with a focus on aspects of natural repair that may be 
pharmacologically augmented to prevent or treat delayed or nonunion fractures (collectively 
referred to as DNFs). The agents covered in this review include recombinant BMPs, PTH/PTHrP 
receptor agonists, activators of Wnt/β-catenin signaling, and recombinant FGF-2. Agents from 
these therapeutic classes have undergone extensive preclinical testing and progressed to clinical 
fracture healing trials. Each can promote bone formation, which is important for the stability of 
bridged calluses, and some but not all can also promote cartilage formation, which may be 
critical for the initial bridging and subsequent stabilization of fractures. Appropriately timed 
stimulation of chondrogenesis and osteogenesis in the fracture callus may be a more effective 
approach for preventing or treating DNFs compared with stimulation of osteogenesis alone. 
 
Introduction 
Fracture healing can be a remarkably robust repair process. After union, a fracture callus can 
achieve structural stability matching or exceeding that of unfractured bone, followed by callus 
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remodeling that restores original bone geometry.1 Yet fracture healing can go awry in 5-10% of 
cases in the form of delayed or nonunion fractures (referred to collectively as DNFs).2;3 Recent 
data specific to open long bone fractures indicated that 17% developed nonunion and another 8% 
exhibited delayed union.4 With delayed union the initial periosteal response ceases before 
fracture bridging,5 while nonunion involves persistent lack of bridging after intramembranous 
and endochondral repair have ceased.6 Nonunions include hypertrophic and atrophic forms. 
Hypertrophic nonunions have substantial non-bridging callus that contains cartilage, and these 
nonunions tend to result from inadequate fracture stability rather than innate biological 
limitations. Atrophic nonunions have minimal callus or cartilage, and usually exhibit scar tissue 
within the fracture gap. The time involved in defining nonunion varies depending on the location 
and type of bone. Longer, larger bones typically need more than 6 months of failed healing 
before being considered a nonunion. 
Several risk factors have been associated with DNFs. Patient-dependent risk factors include older 
age, diabetes, smoking, nutritional deficiencies, and the use of anti-inflammatory agents.3;7 Local 
infection can be particularly deleterious to fracture healing,4 and some components of the 
adaptive immune system may inhibit fracture healing.8 Other local factors associated with DNF 
include the extent of soft tissue injury,9 and compartment syndrome.10;11 Certain skeletal sites 
(e.g. tibia) and types of fractures (e.g. open, comminuted, transverse) are more likely to exhibit 
delayed healing.2;4;12 Most delayed unions eventually heal,5 while others become nonunions in 
the absence of surgical intervention. The great majority of established nonunions require further 
surgical intervention to achieve healing.4 DNFs cause substantial morbidity, loss of productivity, 
decreased quality of life, and extensive health care utilization.12;13 Long bone nonunions can 
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have a particularly devastating impact on health-related quality of life, rivalling or exceeding the 
effects of type 1 diabetes, stroke, or AIDs.14  
A variety of pharmacological interventions show potential for improving fracture healing,3 
almost all of which promote osteogenesis. For various reasons, less attention is paid to the 
important role of chondrogenesis, which creates cartilage that provides initial union of most long 
bone fractures. Perception may account for some of this neglect: DNFs are often associated with 
persistent callus cartilage, which is problematic when it results from delayed or impaired 
conversion to bony callus.15 However, persistent callus cartilage does not necessarily impair 
healing when bony callus development is undiminished.16 Another factor is that analysis of 
chondrogenesis requires time-consuming histomorphometry, and compared with osteogenesis, 
the contribution of chondrogenesis to functional outcomes (e.g. callus strength) is less obvious 
and less amenable to quantification. While often overlooked, chondrogenesis represents a 
potentially important therapeutic target for healing recalcitrant fractures.  
 
Preclinical Fracture Healing Models 
The most commonly used preclinical fracture healing model involves young rodents subjected to 
closed and internally stabilized long bone fractures that heal through intramembranous and 
endochondral bone formation.17 Intramembranous bone is that which forms directly on existing 
bone surfaces, while endochondral bone forms from a cartilage scaffold. The ‘standard’ closed 
fracture model is very useful for studying the biology of fracture healing18 and for identifying 
agents that impair bone healing,19 but may not be ideal for understanding whether an agent might 
prevent or treat DNFs. The standard model typically excludes complicated (e.g. comminuted) 
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fractures that may exhibit delayed healing,16 and spontaneous nonunions are rare.1 With the 
standard model, full biomechanical recovery of fractured bones can occur within 3-4 weeks in 
young mice16 and rats20 in the absence of active treatments. Even agents that do not promote 
osteogenesis or chondrogenesis can increase callus strength in the standard closed fracture model 
by delaying callus remodeling.16  
Other models or model adaptations that mimic aspects of DNFs include local ischemia,21 
adjacent muscle crushing22, surgically open fractures,15 periosteal damage,15;23 externally fixated 
critical-size segmental defects,24;25 and non-rigidly-fixated osteotomy.26 Some of these ‘higher 
hurdle’ models require greater surgical intervention and expertise, which limits their use. But 
delayed healing can also be induced by simple modifications of the standard model, such as the 
use of aged mice,27 aged ovariectomized rats (Figure 1)20 or administering glucocorticoids.28 
 
The clinical landscape for fracture healing trials and indications 
Numerous clinical trials examined pharmacological approaches to accelerate fracture healing,3;29 
with only a handful of successes, as described below. No pharmacological agent or combination 
product (drug plus delivery device) is FDA approved for ‘accelerated fracture healing’, although 
an ultrasound device, Exogen® was approved for this indication.30 In addition to biological 
challenges, clinical trial settings can pose practical challenges to establishing efficacy. The 
window for accelerating radiographic union or return-to-function can be narrow, with most 
placebo patients reaching those endpoints within a few weeks of each other.31;32 Improved 
radiographic union rate is not always accompanied by clinical improvements such as return-to-
function or reduced fracture healing complications,33 which are increasingly relied upon as co-
Au
tho
r M
an
us
cri
pt
primary endpoints. Regulatory approval pathways for acceleration of fracture healing remain 
unclear,29 and no drugs are currently approved for the prevention or treatment of DNFs. The only 
medications approved for fracture healing are bone morphogenetic proteins (BMPs) mixed with 
osteoconductive carriers and administered to open fractures, as described below. There remains a 
clear unmet need for non-surgical and non-biophysical interventions that prevent or treat DNFs.  
 
The Basics of Fracture Healing 
Fracture healing begins with an injury-induced hematoma and inflammation, which promotes the 
condensation of mesenchymal cells from the periosteum, endosteum, and bone marrow and their 
subsequent differentiation along chondrocyte and osteoblast lineages (Figure 2). The earliest 
anabolic response involves intramembranous bone formation on the periosteum. This response 
rarely bridges a fracture by itself,34 and fractures can heal without it,5 but this periosteal bone 
creates a more robust bony scaffold adjacent to the fracture gap upon which the endochondral 
phase can act.23 Bridging of the fractured ends usually occurs through endochondral bone 
formation, starting with chondrocyte production of a cartilaginous scaffold (soft callus) that 
expands to bridge the fractured ends and then mineralizes to form the rigid hard callus (Fig. 2). 
The hard callus is then gradually remodeled by osteoclasts and osteoblasts until normal bone 
geometry is re-established.1 When rigid fixation is achieved in humans after a near-perfect 
reduction, fractures can heal by osteoclasts that create tunnels across the fracture site that refill 
with new bone. This healing, called osteonal, direct, or primary healing, occurs without a 
cartilage intermediate or significant callus.12 Metaphyseal fractures can heal via bone formation 
on existing trabecular elements, which represents another form of primary healing with minimal 
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cartilage or callus. But most fractures heal by the combined effects of intramembranous and 
endochondral bone formation.  
Deficiencies or dysregulation of numerous processes intrinsic to fracture repair can lead to 
impaired healing, including inadequate intramembranous bone formation adjacent to the 
fractured ends, insufficient cartilage formation within the marrow space and fracture gap, 
delayed or premature transition from cartilage to bone, and premature callus remodeling. 
Angiogenesis plays an important role during the endochondral response, and angiogenesis 
inhibitors can severely impair callus formation,19 as can ischemia by other means.21 An 
insufficient early endochondral response, leading to inadequate cartilaginous callus, can 
compromise bony union and also lead to a smaller, less stable hard callus post-union.21;35;36  
 
Natural analogies to fracture healing and the importance of chondrogenesis 
and osteogenesis 
Some fundamental aspects of fracture healing, particularly the endochondral phase, have clear 
parallels with long bone development.3,37 The common reliance on endochondral bone formation 
for fracture healing and long bone development points to natural processes that may be amplified 
to prevent or treat DNFs. Maintaining chondrocytes in an undifferentiated and proliferative state 
is important for creating cartilaginous scaffolds upon which osteoblasts create trabeculae in the 
developing growth plate as well as the hard callus during fracture healing. During development, 
the acceleration of chondrocyte differentiation was associated with reduced growth plate 
cartilage, inappropriate regional cartilage mineralization, and impaired bone growth.38 And 
during fracture healing, accelerated chondrocyte differentiation was associated with reduced soft 
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callus that can lead to a deficient hard callus.36 Such parallels are also evident in the abnormal 
skeletal phenotype38 and impaired fracture healing39;40 of mice deficient in PTHrP, a key factor 
in long bone development (Fig. 3). Conversely, rat studies showed that activation of the 
PTH/PTHrP receptor (PTHR1) led to increased cartilage in the growth plate of unfractured 
femurs, and in the callus of fractured femurs.41  
The importance of chondrocytes and the cartilage they produce is evident in high hurdle fracture 
healing models. Delayed fracture healing in aged mice was associated with reduced 
chondrogenesis compared with young mice.27 Insulin-resistant mice with impaired fracture 
healing exhibited premature chondrocyte differentiation36 and accelerated soft callus 
resorption,35 leading to smaller calluses and prolonged nonunion. In sheep, reduced callus 
cartilage caused by unstable fixation also led to delayed union.26 The impressive healing 
potential of cartilage was shown by the ability of pure cartilage grafts to heal critical size 
segmental defects in mice. This healing was accomplished by cartilage graft mineralization and 
bone formation, which may have been mediated by the transdifferentiation of graft-derived 
chondrocytes into osteoblasts.25  
While cartilage is important for initial union, no amount of cartilage will successfully heal 
fractures without its timely mineralization and replacement with bone matrix. Prolongation of the 
endochondral repair phase led to biomechanically deficient calluses in sheep,42 and persistent 
callus cartilage and its delayed conversion to bone reduced fracture union in rats.43 Drug-induced 
impairment of callus mineralization can also reduce callus strength.44 An ideal pharmacologic 
profile for meeting the unmet needs of fracture healing may involve the promotion or 
maintenance of adequate cartilage to achieve union, while permitting or promoting its timely 
conversion to mineralized bone once union is achieved. Agents that only stimulate osteogenesis 
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can improve the structural integrity of united fractures, but this effect alone may not improve 
outcomes for established or pending nonunions. 
 
Agents and Biological Pathways that Promote Fracture Healing 
The scope of biological modifiers in this review is limited to therapeutic classes that improved 
fracture healing in multiple preclinical studies and progressed clinically to fracture healing trials.  
 
Bone morphogenetic proteins (BMPs) 
BMPs are bone-derived osteoinductive agents that induce bone formation when implanted 
subcutaneously or within bone defects.45 BMPs act by promoting the differentiation of 
mesenchymal stem cells into chondroblasts and osteoblasts.46 The predominant effect of BMPs is 
to stimulate bone formation,47 which increases hard callus development and callus strength.48;49 
However, BMPs also stimulate chondrogenesis during the early stages of fracture healing 
(Figure 4).48;50 Several BMPs and BMP receptors are expressed in fractured bone,18;40 and their 
functional involvement is suggested by the inability of mice lacking BMP-2 to initiate fracture 
healing.51  
A single clinical trial of BMP-7 (OP-1) was the basis for its approval by the FDA for the 
treatment of recalcitrant long bone nonunions where use of autograft is unfeasible and alternative 
treatments have failed.52 The trial tested BMP-7 mixed with a type I collagen carrier, delivered to 
open fractures in 63 patients with tibial nonunions of at least 9 months duration. An active 
comparator group comprised 61 similar patients treated with autologous bone graft. All patients 
Au
tho
r M
an
us
cri
pt
were treated with a locked intramedullary nail. After 9 months, similar and high percentages of 
patients in each group exhibited healing based on radiographic assessments and fracture site 
pain. BMP-7 was FDA-approved in 2001 under a humanitarian device exemption as an 
alternative to autograft.29  
BMP-2 was approved for fracture healing in the form of BMP-2 mixed with an absorbable 
collagen sponge (ACS) delivered locally to open fractures. This combination product ‘device’, 
known as INFUSE® Bone Graft, was FDA-approved in 2004 for use in acute tibial fractures 
treated with an intramedullary nail within 14 days of injury,53 based on data from a randomized 
controlled trial of 450 patients with open tibial fracture. A standard of care (SOC) group was 
treated with reamed or unreamed intramedullary nail fixation, while the BMP-2 group received 
SOC plus BMP-2/ACS. The BMP-2 group exhibited reduced risk of secondary interventions and 
an increased rate of clinical and radiographic healing.54 However, subsequent clinical trials of 
BMP-2 in tibial fractures have not demonstrated efficacy. One trial of BMP-2/ACS in patients 
with open tibial fracture treated with reamed intramedullary nailing did not show improved 
healing, and there was a trend toward a higher infection rate.55 A trial testing BMP-2 in a 
calcium/phosphate matrix, delivered percutaneously to closed tibial fractures, also failed to show 
improvements in healing.31  
The use of BMPs carries some identified safety risks. BMPs can promote regional bone loss by 
recruiting osteoclasts, which can lead to clinical complications.56 BMPs are also associated with 
other complications, including the risk of heterotopic ossification.56 Despite their prevalent use in 
orthopedics through limited indications,57 there remains a need for alternative therapies with 
different biological effects and pharmaceutical presentations. In particular, agents that can be 
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administered to closed fractures without special carriers, grafts or graft substitutes would 
represent a major advance.  
 
PTH receptor (PTHR1) agonists 
PTHR1 agonists have been widely investigated for fracture healing.3 The endogenous PTHR1 
agonists include parathyroid hormone (PTH) and PTH-related protein (PTHrP), which have 
some distinct effects on PTH1R activation58 and clear differences in their endogenous roles. The 
fundamental role of PTH is to maintain calcium, which it does by stimulating bone resorption 
and by promoting renal calcium reabsorption and intestinal calcium absorption. Endogenous 
PTH generally reduces bone mass, as shown by the high bone mass of mice lacking endogenous 
PTH(1-84)59 and humans with hypoparathyroidism.60 Yet paradoxically, intermittent 
administration of exogenous PTH(1-84) or its active fragment PTH(1-34) increases bone mass 
by stimulating bone formation in excess of bone resorption. PTHrP and PTHrP analogs share this 
interesting pharmacodynamic property.61;62  
PTH is not expressed in bone and is not induced after fracture, but its receptor PTHR1 is 
expressed by many cell types, including chondrocytes and osteoblasts.40;63 Systemic PTH 
deficiency in mice was associated with impaired fracture healing,64 and exogenous PTH and 
PTH fragments can increase fracture callus density and strength.41;65;66 PTH promotes early 
chondrogenesis and also osteogenesis in fracture models,41;65;66 which may have favorable 
implications for treatment of DNFs. Indeed, several case reports suggest PTH(1-34) may 
promote healing of DNFs.67-69 A non-placebo-controlled trial of elderly osteoporotic women with 
pelvic factures showed an increased rate of radiographic healing and some clinical improvements 
in those treated with PTH(1-84).70 A placebo-controlled trial of PTH(1-34) in patients with 
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closed distal radius fractures failed to achieve its primary endpoint, but accelerated radiographic 
healing was observed at the lower dose tested.32 A non-placebo-controlled study of PTH(1-34) in 
patients with proximal humerus fractures failed to show improvements in radiographic or clinical 
healing.71 No forms of PTH are currently approved for fracture healing, and no controlled 
clinical trials formally studied whether PTH or PTH(1-34) can prevent or treat DNFs.  
PTHrP has some biological effects that overlap with those of PTH, along with some unique 
attributes that suggest promise for promoting fracture healing. Unlike PTH, PTHrP has 
fundamental endogenous roles in bone development and fracture healing. Whereas the primary 
role of PTH is to maintain serum calcium, often at the expense of bone mass,59 PTHrP is 
considered an endogenous bone anabolic factor that acts by promoting osteoblast differentiation, 
survival, and activity.72 PTHrP also inhibits terminal chondrocyte differentiation, maintains 
chondrocyte proliferation, inhibits chondrocyte apoptosis, and prevents premature cartilage 
mineralization.38;73-75 PTHrP is expressed by osteoblasts during the intramembranous phase of 
fracture healing, and by mesenchymal cells, proliferating chondrocytes and osteoblasts during 
the endochondral healing phase.76 PTHrP is functionally expressed in the intact and the fractured 
periosteum of rodents.77;78 Periosteal PTHrP mRNA was rapidly upregulated in fractured mouse 
bone, and ablation of periosteal PTHrP impaired fracture healing by reducing callus cartilage, 
bony callus, and callus size.40 It is tempting to speculate that the loss of periosteal PTHrP 
contributes to the strong inhibitory effects on fracture healing that can result from periosteal 
damage.15;23  
Consistent with its endogenous role in the maintenance of bone mass, exogenous PTHrP 
administration has strong bone anabolic effects in humans and animals. An early PTHrP study in 
rats indicated dose-dependent BMD gains that exceeded the effects of PTH(1-34).61 Recently, 
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abaloparatide, a selective PTH1R activator with homology to PTHrP, was reported to cause 
significantly greater BMD gains compared with PTH(1-34) in postmenopausal women.79 PTHrP 
and PTHrP analogs have yet to be clinically tested in fracture healing trials, but preclinical 
studies indicate positive effects of PTHrP in models of impaired bone healing. A PTHrP analog 
improved the density and strength of rabbit osteotomy sites, overcoming the detrimental effects 
of glucocorticoids.80 The negative impacts of glucocorticoids on fracture healing81 may relate at 
least in part to their ability to suppress bone cell production of PTHrP.82 Exogenous PTHrP 
enhanced the size and density of calluses in diabetic mice with impaired fracture healing83 
PTHrP administration also upregulated pro-angiogenic factors in a diabetic bone regeneration 
model.84 The latter finding suggests the potential for PTHrP to overcome the suppression of 
angiogenesis that can impair bone healing in diabetes. Endogenous PTHrP expression, which 
was markedly reduced in the regenerate bone of diabetic mice, was largely restored by 
exogenous PTHrP.84 In healthy mice, PTHrP mRNA expression was upregulated throughout the 
post-fracture healing process, and PTH administration further increased PTHrP expression in the 
healing fractures in association with enhanced chondrogenesis and osteogenesis (Fig. 5).66 Thus 
it appears that bone anabolism through PTH1R activation can increase endogenous PTHrP 
expression in fracture sites, which could perhaps lead to a virtuous cycle that promotes 
chondrogenesis and osteogenesis. An important role for endogenous PTHrP in chondrogenesis 
and osteogenesis was indirectly demonstrated by impaired fracture healing in PTHrP-deficient 
mice (Figure 3).39  
These findings indicate that PTHR1 agonists exert diverse biological effects that may favor 
fracture healing. Endogenous PTHrP and exogenous PTHrP and PTH can maintain chondrocytes 
in an undifferentiated and proliferative state while stimulating osteogenesis by osteoblasts. In 
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low- and high-hurdle fracture healing models, PTHrP and PTH promoted the production and 
maintenance of cartilaginous callus for bridging and union, while stimulating bone formation to 
enhance callus strength. Clinical data with PTH(1-34) show some beneficial effects in 
accelerating fracture healing, but it remains to be tested whether PTH, PTHrP or analogs thereof 
can prevent or treat DNFs.  
 
Activators of Wnt/β-catenin signaling  
Recent comprehensive reviews have described Wnt/β-catenin signaling pathways85 and how they 
may be leveraged in orthopedic settings.86 Wnts represent a large family of secreted factors that 
activate signaling pathways, with prominent roles in embryonic development and tissue 
regeneration.85 Wnts stimulate bone formation by activating low density lipoprotein receptor 
related protein-5 (LRP5) or LRP6 and Frizzled co-receptors on the cell surface, which leads to 
activation of β-catenin signaling.87 When endogenous Wnt inhibitors prevent Wnt from 
activating these co-receptors, bone formation is suppressed.87 Two prominent Wnt inhibitors are 
sclerostin and DKK1.88 Inhibition of sclerostin or DKK1 via loss-of-function mutations or 
inhibitory antibodies can increase bone formation and bone mass in intact animals.88 Antibodies 
that inhibit DKK1 89 or sclerostin 90;91 can also increase callus strength in animals with 
experimental fractures, and their subcutaneous route of administration would potentially allow 
for the treatment of open or closed fractures.  
While other anabolic agents covered in this review are direct receptor agonists, sclerostin and 
DKK1 antibodies function as inhibitors of inhibitors. This may be an important distinction 
because the timing, location and magnitude of effects of sclerostin or DKK1 antibodies will 
depend on the presence and levels of endogenous sclerostin, DKK1, and free Wnts. Sclerostin 
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antibody administration to rats increased skeletal mRNA expression of the Wnt inhibitor Dkk1 
by nearly 10-fold,92 and endogenous DKK1 appears to be one factor that limits the ability of 
sclerostin antibodies to increase bone mass and callus strength.93 There are additional Wnt 
inhibitors besides sclerostin and DKK185 that may also inhibit Wnt signaling despite the 
administration of DKK1 or sclerostin antibodies. BMPs have their own endogenous inhibitors 
that can reduce BMP receptor activation.94 PTH and PTHrP have no validated endogenous 
inhibitors that impair PTH/PTHrP receptor activation.  
The remainder of this section will focus on sclerostin antibodies because, unlike DKK1 
antibodies, their anabolic effects on bone have been corroborated in humans.95 Sclerostin 
antibodies increased bone formation in a variety of orthopedic models, including implants,96 
osteotomies,90;97 bone defects,24 and long bone fractures.98;99 However, sclerostin antibodies have 
not been shown to have pro-chondrogenic effects in bone healing models,24;90;97-99 and several 
studies showed that sclerostin inhibition reduced the volume or balance of cartilage in fracture 
calluses (Figure 6).90;91;97-99 These findings align with developmental biology wherein Wnt/β-
catenin signaling appears to inhibit differentiation of mesenchymal stem cells along the 
chondrocyte lineage, while promoting their differentiation to the osteoblast lineage.100 
Interestingly though, inhibition of Wnt/β-catenin signaling in the chondrocyte lineage of 
transgenic mice with tibial fractures was associated with a marked suppression of early callus 
chondrogenesis, along with reduced bony callus formation and decreased callus strength.101 Thus 
while endogenous PTHrP appears to have similar anabolic roles during bone development and 
fracture healing, the roles of Wnt/β-catenin signaling in these two processes may have some 
divergence. It is important to note that reductions in callus cartilage with sclerostin inhibition has 
not been associated with any untoward effects on healing, presumably because bony callus 
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formation remains robust. However there is little evidence that sclerostin inhibition promotes 
cartilage formation. Similarly, Wnt3a, a direct activator of wnt/β-catenin signaling, has been 
shown to promote skeletal repair via intramembranous rather than endochondral bone 
formation.102 The effect of sclerostin antibodies or other activators of Wnt/ β-catenin signaling in 
bone may be limited to increased osteogenesis, and for those fractures destined to achieve union, 
this effect should increase callus strength. But for a pending or established nonunion, it is not 
clear that increased bone formation alone would improve outcomes. In a bony defect model 
characterized by frequent nonunions, sclerostin antibody provided minimal efficacy beyond the 
modest addition of non-bridging bone at the defect margins.103  
Two placebo-controlled clinical trials assessed the effects of a sclerostin antibody 
(romosozumab; AMG 785/CDP7851) on fracture healing. One study (clinicaltrials.gov: NCT 
00907296) involved adults with fresh tibial shaft fractures treated with an intramedullary nail, 
with the hypothesis that romosozumab would reduce radiographic healing time. The other study 
(clinicaltrials.gov: NCT01081678) involved adults with a fresh unilateral hip fracture treated 
with post-surgical fixation, with the hypothesis that romosozumab would accelerate healing of 
hip fractures and improve physical functioning. Results of these studies had not been presented 
publically as of early 2016, but the sponsors indicated they would not pursue fracture healing 
indications due to the nature of the efficacy results, as well as recent regulatory guidance that 
suggested challenges in achieving registration for accelerated fracture healing.104 When fracture 
union and callus strength were assessed in animals prior to complete bridging and biomechanical 
recovery, sclerostin inhibition did not lead to acceleration of fracture healing.93;98 
Au
tho
r M
an
us
cri
pt
Fibroblast Growth Factor-2 (FGF-2) 
FGF-2 is a potent mitogen with pleiotropic skeletal and extraskeletal effects. Systemically 
injected recombinant FGF-2 increased bone formation in ovariectomized rats,105 and FGF-2 
inhibited terminal differentiation of cultured chondrocytes,106 suggesting FGF-2 may promote 
osteogenesis and chondrogenesis. In a nonhuman primate study, internally fixated ulnar 
osteotomies that were subjected to periosteal stripping had a 40% nonunion rate in a control 
group treated with empty hydrogel carrier, whereas all animals in a group treated with FGF-2 in 
hydrogel achieved union.107 Biomechanical assessments of calluses that achieved union showed 
significantly greater strength in the FGF-2 group versus controls, consistent with increased 
osteogenesis. Histology was not assessed until the healed animals had stable calluses, so effects 
of FGF-2 on cartilage could not be properly assessed. Nonetheless, the combined effects of 
increased union and increased strength of the post-union calluses represents a high standard of 
preclinical evidence, and suggests FGF-2 has the potential to prevent or treat DNFs. A placebo-
controlled clinical trial was conducted for FGF-2 delivered percutaneously in hydrogel to closed 
tibial fractures.108 Inclusion criteria included transverse or short-oblique fracture morphology, 
which tend to heal more slowly than oblique or spiral fractures. Over a 24-week period, a greater 
percentage of patients in the FGF-2 group achieved radiographic union (bridging of all four 
cortices). However there was no treatment effect on the rate at which fractures showed bridging 
of 3 of 4 cortices, and no difference in clinical healing endpoints. FGF-2 is not currently 
indicated for fracture healing, and it is unclear whether registration trials for FGF-2 will be 
conducted. 
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Summary  
The ultimate fates of FGF-2, sclerostin antibody, PTH, PTHrP and other bone-active factors for 
fracture healing are unknown, but experiences with these agents and with BMPs provide clues as 
to the attributes of therapeutic agents that may someday prevent or treat DNFs. All agents 
summarized in this review can increase bone formation, volume, density and strength. Some 
agents (PTH, PTHrP, FGF-2) regulate the proliferation and differentiation of chondrocytes in 
ways that maintain their ability to produce cartilage, whereas sclerostin inhibitors and other 
activators of Wnt/β-catenin signaling appear to favor osteogenesis over chondrogenesis. Some 
agents (BMPs and PTHrP) are expressed locally and functionally during fracture healing, 
suggesting physiological roles during repair that could be pharmacological augmented. Some 
agents are delivered to open fractures in special carriers (BMP-2, BMP-7), while others can be 
administered systemically (PTH, PTHrP, sclerostin antibody) or percutaneously to closed 
fractures (FGF-2, and potentially PTH, PTHrP or sclerostin antibody). With the possible 
exception of sclerostin antibody, for which clinical fracture healing data have yet to be 
published, each agent produced some benefits in patients with fractures, though none has been 
tested in controlled clinical trials of patients with existing DNFs or with closed fractures at high 
risk of DNF.  
DNFs have varying etiology and pathophysiology, and it is unlikely that one therapy will have 
universal utility in all at-risk patients. Genetic or serum-based factors have been explored as a 
way of identifying patients at risk for nonunion,109 and such biomarkers might someday help 
tailor adjuvant therapies based on patient- and fracture-specific characteristics. In the meantime, 
there seems to be a critical interplay during fracture healing between cartilaginous and 
osteogenic processes that may be exploited to favorably influence outcomes for a range of DNFs.  
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A final proposal relates to translational aspects of preclinical fracture models. Many agents 
increase callus density and strength in the standard rodent closed fracture model, where union 
and biomechanical recovery is likely without treatments, but agents under development for 
DNFs require a higher level of preclinical evidence for proof of concept. Increased callus 
strength above and beyond that of unfractured bone is a common finding in the literature that 
does not by itself indicate potential to improve DNF outcomes. For research programs focused 
on DNF indications, preclinical efficacy in a true non-union model represents the strongest proof 
of concept. Alternatively, modifications to the standard closed fracture model can lead to delayed 
healing, and treatment-related increases in callus strength in these higher-hurdle models may 
suggest the potential for improving DNF outcomes. When relying on the standard rodent fracture 
model, hints of therapeutic potential for DNFs may require biomechanical assessments at early 
post-fracture time points, when strength recovery in untreated controls is far from complete. 
Histologic assessments conducted before full strength recovery is also recommended to allow 
proper evaluation of treatment effects on cartilage. For programs directed towards DNFs, a 
promising histological profile may include an early increase in callus cartilage, followed (post-
bridging) by an increase in its mineralization and conversion to bone. This profile should lead to 
improved strength of fractures that would have healed on their own, and may also promote union 
and strength recovery of fractures that would not.  
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Figure Legends 
 
Fig. 1. Biomechanical strength recovery of internally stabilized closed femoral fractures created 
in normal gonad-intact female rats at 8 weeks of age (white circles), and in OVX rats at 32 (grey 
circles) or 50 (black circles) weeks of age. Animals were sacrificed at various time points after 
fracture for biomechanical testing of callus breaking load by a 3-point bending test. Data 
represent percentage of the non-fractured contralateral femur diaphysis, n = 3-10 per group per 
time point. Fractured femurs from older OVX rats showed slower regain of strength compared 
with young gonad-intact rats. Reproduced with permission from Meyer et al.20 
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Fig. 2. Stages of fracture healing in rodents subjected to internally stabilized experimental long 
bone fractures, as described by Bonnarens and Einhorn.17 Reproduced with permission from 
Hadjiargyrou et al.110 
 
Fig. 3. Impaired long bone fracture healing in PTHrP haplo-insufficient mice compared with 
wild-type (WT) mice. PTHrP(+/-) mice exhibited an early transient deficit in callus cartilage a 
more sustained deficit in callus size and bone content. Day 7 and 14 refer to the time after 
creation of internally stabilized closed femoral fracture. Data represent means ± SD, n = 6/group. 
* Significant differences versus wildtype (WT) controls, p<0.05. Reproduced with permission 
from Wang et al.39 
 
Fig. 4. Recombinant human BMP2 (rhBMP2) induced cartilage formation during the repair of 
stabilized closed long bone fractures in mice. Mice received PBS (control) or 10 µg of rhBMP2 
by direct injection into the fresh fracture site, and were sacrificed 10 days later. Upper graph: 
Total callus volume and callus cartilage volume were significantly greater in the rhBMP2 group 
vs. PBS controls when measured by histomorphometry 10 days post-fracture (**P<0.05). Lower 
images: Safranin-O/Fast Green staining of callus sections, with a higher-magnification image 
showing chondrocytes spanning the fracture line that is near the left side of the inset. Reproduced 
with permission from Yu et al. 49 
 
Fig. 5: Changes in PTHrP, Wnt signaling (i.e., beta-catenin), chondrogenesis and osteogenesis in 
normal mice after creation of internally stabilized closed femur fractures. Mice were treated with 
PTH(1-34) (30µg/kg/day) for 14 days post-fracture. Healing fractures were harvested at various 
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times and assessed by histology (left panels) or by RNA analyses (right panels). Histology 
sections obtained 5 and 10 days post-fracture were stained with Safranin O/fast green, which 
labels cartilage and chondrogenic cells (red color). The right panels show that PTH(1-34) 
increased mRNA expression of PTHrP, the chondrogenic marker Sox9, the osteogenic marker 
Runx2, and the Wnt signaling marker beta-catenin. Reproduced with permission from Kakar et 
al.66 
 
Fig. 6. Histomorphometry of callus composition for normal wild-type (WT) mice and Sost 
knockout (KO) mice subjected to internally stabilized closed femoral fractures. Data were 
generated on samples collected 14 or 28 days post-fracture. Data represent means and SEM, n = 
6-10/group/time point. *P<0.05 for SOST KO vs. WT. Reproduced with permission from Li et 
al.99 
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